Introduction
Nuclear medicine imaging methodologies, positron emission tomography (PET) and single photon emission computed tomography (SPECT), provide a unique capability to noninvasively visualize regional biochemical and physiological functions in living humans, by administration of radioactive molecules as a probe. 1 Therefore, this technology has been clinically used in the diagnosis and staging of various diseases. Furthermore, this technology has been applied to a direct in vivo measurement of drug effectiveness in humans, highlighting the essential information needed in the fields of drug development including pharmacology, toxicology, gene targeting, and pharmaceuticals. [2] [3] [4] [5] [6] [7] [8] In recent years, by exploiting new detection technologies, several high-resolution PET and SPECT systems have been developed for imaging the biodistribution of a radiolabeled molecule in small laboratory animals. [5] [6] [7] [8] [9] These devices permit noninvasive and repetitive imaging of both the temporal and the spatial biodistribution in a single living animal. Therefore, by the repetitive use of the same animal, the technology has enabled the removal of the variability caused by inter-animal differences and the use of each animal as its own control, indicating that it is useful especially when genetically engineered and tissue transplanted animal models of disease are used. An additional advantage of using PET and SPECT systems in small animal models is that the technology provides a direct connecting link between the animal model and human studies. Thus, high-resolution PET and SPECT systems for small laboratory animals have the capacity to make a valid and unique contribution to drug development.
One important application of these nuclear medicine imaging methodologies in the field of drug development research may be neuroreceptor and transporter binding studies in small animal models of various diseases. [3] [4] [5] [6] [7] 9, 10 This study focuses on this application; drugs for the treatment of Parkinson's disease were evaluated with a small-laboratory-animal SPECT system developed recently (Fig. 1 ).
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N-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is metabolized to MPP + by MAO-B in the brain after penetration into the blood-brain barrier, and the MPP + produced destroys nigrostriatal dopamine nerves and produces irreversible neurodegeneration associated with Parkinsonian syndrome detected in patients. [12] [13] [14] [15] On the other hand, the monoamine oxidase (MAO) inhibitor, deprenyl, has been reported to be effective in patients with Parkinson's disease. 12, 14, 15 In this study, to gain further understanding of the efficacy of this drug, deprenyl was administered to MPTP-treated common marmosets and a nuclear imaging study was performed with two radiolabeled ligands, [ High-resolution single photon emission computed tomography (SPECT) provides a unique capability to image the biodistribution of radiolabeled molecules in small laboratory animals. Thus, we applied the high-resolution SPECT to in vivo imaging of the brain dopaminergic neurotransmission system in common marmosets using two radiolabeled ligands, 
Experimental
Animal experiments were conducted in accordance with our institutional guidelines, and the experimental procedures were approved by the Kyoto University Animal Care Committee.
Animal preparation
Common marmosets (Callithric jacchus) weighing 317 -399 g (bred by Shin Nippon Biomedical Laboratories, Ltd., Kagoshima, Japan) were housed individually in stainless steel cages in a temperature/humidity-controlled (28 ± 2˚C and 50 ± 10%, respectively) animal room, on a balanced marmoset diet (CMS-1, CLEA Japan, Inc.) with water ad libitum.
Parkinsonism was induced in common marmosets by MPTP, according to the method of Nomoto et al. 13, 18, 19 Briefly, animals were injected orally with deprenyl (Chinon Pharmaceutical and Cheminal Co.) at a dose of 10 mg/kg, and 2 h after the deprenyl treatment, treated intravenously with MPTP (Research Biochemicals International) at a dose of 2.5 mg/kg following anesthesia with ketamine, followed by the same treatment 1 week later. Normal marmosets received vehicle injections and were used as control animals. Three marmosets were treated with deprenyl-MPTP, three animals with saline-MPTP, and three animals with saline-alone. Two months after the last treatment, the marmosets received behavioral testing and SPECT studies.
Motor behavior
The common marmoset was removed from the home cage to the test cage, in isolation from other animals in the colony. The test cages were equipped with three infrared photocells to estimate the amount of locomotion of the animal. Motility counts were accumulated for 6 h according to the method of Nomoto.
18,19

Preparative and analytical HPLC system for radiolabeling
The HPLC system used was a SHIMADZU LC-6A, SPD-6A UV spectrophotometric detector (Shimadzu Co., Kyoto, Japan), attached to an on-line radioactivity detector (Aloka NDW-351D NaI(Tl) scintillation radioisotope detector, Aloka Co., Ltd., Tokyo, Japan) using the following systems:
System A: LICHROSORB RP18-5 (7.5 × 300 mm) column (Chemco Scientific Co., Ltd., Osaka, Japan), 75:25 (v/v) mixture of methanol and water containing 0.2% triethylamine, and a flow rate of 1.5 ml/min.
System B: COSMOSIL 5C18-300 (10 × 250 mm) column (Nacalai Tesque Inc., Kyoto, Japan), 70:30 (v/v) mixture of methanol and water containing 0.2% triethylamine, and a flow rate of 3.0 ml/min. System C: COSMOSIL 5C18-AR-300 (4.6 × 150 mm) column (Nacalai Tesque), 70:30 (v/v) mixture of methanol and water containing 0.2% triethylamine, and a flow rate of 1.0 ml/min.
Radiolabeling procedure for [ 123 I]β-CIT and [ 123 I]IBZM
The radioiodination of [ 123 I]β-CIT, a ligand for DAT imaging, was accomplished by oxidative alkylstannyl-[ 123 I]iodide exchange reaction as described previously with slight modifications. 16 Briefly, 2β-carbomethoxy-3β-(4-trimethylstannyl-phenyl)tropane (RBI) was reacted with nocarrier-added sodium [
123 I]iodide (Nihon Medi-Physics Co., Ltd., Hyogo, Japan). Hydrogen peroxide was used as an oxidizing agent. The reaction mixture was loaded onto a SEP-PAK C18 Cartridge (Waters Co., Milford, MA, USA), and eluted with water, followed by ethanol to obtain [ 123 I]β-CIT. After evaporation, [ 123 I]β-CIT was dissolved finally into a solution of saline with 5% ethanol. The radiochemical purity of [ 123 I]β-CIT determined by reversed phase HPLC (System A) was greater than 95%. All radioactive compounds were eluted within 40 min after injection into the HPLC column. The total radiochemical yield was 55%; although the specific radioactivity could not be directly measured, it was more than 0.185 TBq/µmol.
[ 123 I]IBZM, a ligand for D2R imaging, was radiosynthesized according to the Chloramine T method reported previously, 17 with several modifications.
Briefly, (S)-(β)-2-hydroxy-6-methoxy-N-[(1-ethyl-2-pyrrolidinyl)methyl]benzamide (RBI) was reacted with no-carrier-added sodium [ 123 I]iodide in the presence of Chloramine T as the oxidant. The reaction mixture was then extracted with ethyl acetate. After evaporation, the residue was dissolved in methanol, followed by reversed phase HPLC purification (System B). [
123 I]IBZM was prepared for injection similarly to [ 123 I]β-CIT, and then analytical HPLC was performed (System C). The radiochemical purity was greater than 95%, the total radiochemical yield was 30%, and the theoretical specific radioactivity was 8.88 TBq/µmol.
SPECT study
SPECT studies were performed before and 1, 2 and 6 months after initial haloperidol or sulpiride treatment. During the period of investigation, drug treatment was suspended. For imaging procedures, anesthesia consisted of a ketaminexylazine cocktail (20 mg/kg and 3 mg/kg, respectively, i.m.), followed by pentobarbital sodium (20 mg/kg, i.p.). All animals received a single bolus of [ 123 I]β-CIT (150 -200 MBq) into the saphenous vein, and 240 min later, data acquisition was started as dynamic SPECT scans (360˚ rotation, 40 s/frame for 32 frames), using a SPECT 2000H-40 gamma camera (Hitachi Medical Co., Tokyo, Japan) with specially designed pinhole collimators (30% window; 159 keV energy peak; 128 × 128 matrix mode; pixel size of 1.33 mm) connected on-line to an RW-3000 data processor as reported previously 11 (Fig. 1) . After one week, no radioactivity was detected in an animal; then For the dynamic study, five consecutive slices (total slice thickness of 3.85 mm) of the brain were summed for data analysis. Regions of interest (ROIs) were drawn onto the left and right striatum (st) and onto the cerebellum (ce) in the sagittal and/or transaxial SPECT images. Accumulation of radioactivity at each ROI, acst and acce (% injected dose/ml) was measured, after which the value of -1 = was calculated as Binding Ratio (BR). 20 Since acst and acce were regarded as total binding and nonspecific uptake of radioligand, respectively, acst minus acce corresponded to the specific binding of radioligands in the striatal area. Consequently, BR indicated specific binding/nonspecific uptake, which was proportional to the binding potential (Bmax/Kd). 21 
Measurement of dopamine concentration in the striatum
The striata of animals after SPECT studies were dissected out. The tissue was homogenized in ice-cold perchloric acid (50 mM) using a Potter-Elvehjem homogenizer, followed by centrifugation at 15000g for 20 min at 4˚C. The supernatant was passed through a 0.2-µm membrane filter to prepare the HPLC sample.
Ten microliter aliquots of the supernatant sample were applied into an HPLC system with a reverse phase column (Biophase 
Statistical analysis
The data were analyzed by the Tukey-Kramer multiple comparisons test. P < 0.05 was regarded as significant.
Results
SPECT measurement of [ 123 I]β-CIT and [ 123 I]IBZM binding
To evaluate [
I]β-CIT and [
123 I]IBZM kinetics in the brain, each ligand was injected in normal common marmosets, then the regional accumulation of radioactivity was measured by SPECT to prepare the time-activity curve (Fig. 2) . Imaging was performed from 15 min to 240 min for [ 123 I]β-CIT and to 90 min for [ 123 I]IBZM after injection. As it was reported previously that dopaminergic synapses are present at a high density in the striatum but are lower in the cerebellum, ROIs were drawn onto the striatum and cerebellum, and the radioactivity values in these two areas, acst and acce (% injected dose/ml), were measured against time. In the striatum, the amount of [ 123 I]β-CIT activity increased gradually and reached a plateau about 180 min postinjection.
In the cerebellum, a similar accumulation of radioactivity was observed immediately after injection, but it was washed out and reached a constant value 150 min after injection.
[ 123 I]IBZM showed a rapid accumulation and slow clearance in both regions. However, the clearance rate in the striatum was slower than that in the cerebellum. The ratio of the in vivo specific binding value of radioligand to nonspecific uptake, i.e. BR, became constant at 240 min and 60 min after injection of [ 123 I]β-CIT and [ 123 I]IBZM, respectively. Therefore, in further studies, these points were set as acquisition times to gain data for the calculation of BR. (Fig. 4 (A) , uptake of radioactivity in the striatum (% injected dose/g of tissue) (acst); , uptake of radioactivity in the cerebellum (% injected dose/g of tissue) (acce); , Binding Ratio (BR) ([acst -acce]/ acce).
(1.11 ± 0.15 for vehicle-treatment, 1.13 ± 0.20 for MPTPtreatment) (Fig. 4 (B) ). In the behavioral study, locomotor activity was significantly decreased in the MPTP-treated animals (712 ± 497 counts/6 h for vehicle-treatment, 141 ± 92 counts/6 h for MPTP-treatment) (P < 0.05, vs. vehicletreatment) (Fig. 5) .
The pretreatment of deprenyl in the MPTP-treated marmosets increased the striatal uptake of [ 123 I]β-CIT and BR of [ 123 I]β-CIT, and a similar BR to the vehicle-treated condition was observed (2.74 ± 0.36) (Fig. 4 (A) ). BR of [ 123 I]IBZM in the deprenyl-MPTP-treated animals (1.10 ± 0.26) showed no changes compared with the non-treated and MPTP-treated groups (Fig. 4 (B) ). Locomotor activity in the MPTP-treated animals was increased by the pretreatment of deprenyl and reached substantially the same level as that in the control group (1103 ± 752 counts/6 h) (Fig. 5) . The changes in striatal uptake of [ 123 I]β-CIT agreed well with the changes in locomotor activity.
Striatal dopamine concentration
After the SPECT study, the striata were excised, and then dopamine (DA) concentration was measured by HPLC. The concentration of DA in the MPTP-treated animals was significantly lower than that in the vehicle-treated control group (11.5 ± 1.3 µg/g tissue for vehicle-treatment, 2.0 ± 0.6 µg/g tissue for MPTP-treatment) (P < 0.01, vs. vehicle-treatment) (Fig. 6) . On the other hand, the concentration of DA in the deprenyl-MPTP-treated animals was the same as that in the vehicle-treated control group. Thus, the pretreatment of deprenyl completely protected against MPTP-induced depletion of DA in the striatum in the MPTP-treated animals
Discussion
In the SPECT imaging studies, the estimation of specific uptake of radioactivity related to neurotransporters and receptors is important. In this study, to perform semiquantitative analysis of dopaminergic neurotransmission in SPECT studies, ROIs were set on the striatum, which has a high density of DAT and D2R, and the cerebellum, in which these molecules are present at a very low density. [22] [23] [24] Therefore, since the nonspecific uptake in the stratum is assumed to be comparable with that in the cerebellum, the specific binding in the striatum can be calculated by subtracting the concentration of radioactivity in the cerebellum from the total concentration of radioactivity in the striatum. Thus, in this study, the specific to nonspecific binding ratio in the striatum (BR) was regarded as the index of ligand affinity and/or density of DAT or D2R in this region.
Deprenyl has been reported to be effective in patients with Parkinson's disease. 14, 15, 25 Thus, to gain further understanding of the efficacy of this drug, deprenyl was administered to MPTP-treated common marmosets and a SPECT imaging study was performed with two radiolabeled ligands, [ 123 I]β-CIT as a DAT ligand for the evaluation of the pre-synaptic function and [ 123 I]IBZM as a D2R ligand for the evaluation of the postsynaptic function. BR of [ 123 I]β-CIT in the striatum was significantly low in the MPTP-treated animals compared with the control group. This finding indicates the destruction of presynaptic dopamine neurons by MPTP. In contrast, a similar BR to the control group was observed in the pretreatment of deprenyl in the MTPT-treated animals. However, BR of [ 123 I]IBZM showed no changes among the control, MPTPtreated, and deprenyl-MPTP-treated groups. These findings of IBZM imaging indicate that MPTP and deprenyl do not affect the post-synaptic function. These results of SPECT imaging agreed well with those of DA concentration and motor behavior. Thus, the SPECT imaging study clearly demonstrated that the neuroprotective effect of deprenyl on Parkinsonism is due to the protection of the destruction of presynaptic DA neurons, although the mechanism of action of deprenyl is complex 15 and further studies are required to elucidate the neuroprotective mechanism of deprenyl.
The spatial resolution of animal SPECT used at present is not so high compared with non-invasive anatomical imaging modalities, such as X-ray computed tomography (CT) or magnetic resonance imaging (MRI). 5, 7 The information content of SPECT images only incidentally provides anatomical landmarks. Thus, a much better approach would be to combine SPECT imaging with high-resolution anatomical imaging by CT or MRI to provide direct determination of both biological function and anatomy. The most efficient and accurate way to do this is to develop integrated multimodality imaging systems, such as a SPECT/CT device and SPECT/MRI device. 5, 7 These devices will also provide an improvement in the quality of SPECT images through the use of anatomic information.
